Compare Amphastar Pharmaceuticals Inc (AMPH) vs Dow Inc (DOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Dow Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Dow Inc trades at $29.31 (market cap $20.92B). The key difference: Dow Inc is far larger — about 25.3× Amphastar Pharmaceuticals Inc's market cap, and Dow Inc pays a 4.82% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | DOW | |
|---|---|---|
Market Cap | $826.08M | $20.92B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $41.87 |
52-Week Low | $16.87 | $20.65 |
Enterprise Value | $1.22B | $36.70B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
DOW trades at $29.03, up 1.86% today, but remains in a bearish technical trend with support near $28. The company reported a net loss of $2.62 billion in 2025, with negative profit margins and declining revenue, though it has beaten EPS estimates in recent quarters. Analyst consensus is a 'Hold' with a $36.11 price target, indicating potential upside if fundamentals improve.
The outlook is cautious; while liquidity supports dividends and the stock trades below book value, persistent losses and high debt pose significant risks. Investor sentiment is mixed amid broader market volatility, with earnings performance being the critical factor for any sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →
